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Introduction: Anaplastic thyroid carcinoma (ATC) is a killer tumor, characterized by local invasiveness,
risk of recurrence and very poor prognosis. Due to its rarity, clinical case studies concerning management
are lacking.
Methods: We retrospectively reviewed a multinstitutional clinical series of 114 consecutive patients
treated between 1996 and 2012 for ATC. The outcomes of a combined treatment were analyzed
considering the impact of surgery and radiotherapy on survival.
Results: Patients were divided in groups A and B considering tumor size (tumor lesser and larger than
5 cm). Surgery was carried out in 71 patients, radiotherapy in 89 patients. Tracheostomy and endo-
prothesis were used respectively in 48.7% and in 25.6% of patients. The mean survival was 5.35 (±3.2)
months with no signiﬁcant difference in group A vs group B. A better survival was observed in both
groups of patients undergone a surgical treatment compared to no treated patients (p ¼ 0.001 and
p ¼ 0.0001) or to patients undergone radiotherapy alone (p ¼ 0.047 and p ¼ 0.0001). Combination of
surgery and radiotherapy signiﬁcantly improved outcome (p ¼ 0.017).
Discussion: Despite disappointing results from single therapeutic approach, multimodal strategy has
progressively become the treatment of choice in ATC, with surgery being the cornerstone of the
management.
Conclusion: Although dismal prognosis, the combined treatment might signiﬁcantly improves locore-
gional disease control, achieving acceptable survival in selected patients and adequate palliation of the
symptoms.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Thyroid cancer is the most common endocrine tumor, repre-
senting the 0.7e1% of all neoplasms; its incidence is continuously
increasing with 8.7 cases every 100.000 inhabitants in the USA
[1,2].
Differentiated carcinomas (DTC) are 94% of all tumors whereas
medullary carcinoma (MTC) [3,4] and anaplastic carcinoma (ATC)
represent respectively 4.5% and 1.5% of cases. The female/male ratiozo).
f of Surgical Associates Ltd.is 5 to 1 with a peak of incidence in the sixth and seventh decades
[1]. The 5-years survival rate is 94% for differentiated tumors and
5.6e11.4% for anaplastic carcinoma [5,6]. Although ATC accounts for
less than 2% of all thyroid malignancies, it results in up to 40% of
deaths related to thyroid cancer.
A large number of ATCs is diagnosed in patients with history of
longstanding goiter or incompletely treated papillary or follicular
thyroid carcinomas. In fact, a careful histopathologic examination of
ATC often reveals a papillary structure or follicular components in
focal areas of the tumor. ATC is supposed to derive from a terminal
process of dedifferentiation of carcinoma. The tumor may replace
most of the thyroid gland and invade the surrounding structures. Its
microscopic features include three distinct morphologic patterns:
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mutated in ATC as result of evolution from RAS-mutated follicular
thyroid carcinomas [8].
Therefore, ATC is the most lethal among all thyroid cancers
with a median life expectancy of about 4e9 months. In sharp
contrast with DTCs, only 10%e15% of patients are alive two years
after diagnosis. At the time of ﬁrst clinical observation, patients
usually present a rapidly enlarging anterior neck mass, with
compressive symptoms such as dyspnoea, dysphagia and vocal
cord paralysis [9]. In almost 70% of patients, as observed in large
series, is possible to demonstrate an invasion of surrounding
structures: muscles (65%), trachea (46%), oesophagus (44%),
laryngeal nerve (27%), and larynx (13%). At the time of diagnosis,
lymph node metastases are observed in almost 40% of the pa-
tients, while up to 50% of cases experiences distant metastases.
Lung, bone, skin, and brain are the most frequent site of meta-
statization [7,10]. Death is often caused by tracheal and
oesophageal invasion and obstruction, as well as metastatic
involvement.
Aim of the study was a retrospective analysis of a large multi-
nstitutional clinical series of three referral centres for endocrine
surgery, evaluating the impact of a combined treatment in ATC
patients.
2. Patients and methods
2.1. Patients
One hundred and fourteen consecutive ATC patients, 68 women
(59.7%) and 46 males (40.3%), with a mean age of 72.6 ± 8.7 years,
referred to three Italian Endocrine Surgery Units between 1996 and
2012 were considered for the analysis. Fine-needle cytology (FNC)
conﬁrming or suspecting an ATC diagnosis was performed for any
patient.
Preoperative staging consisted of laryngoscopy, neck ultraso-
nography, bone scan and computed tomography (CT) of head, neck,
mediastinum, thorax, and abdomen to determine the extent of
inﬁltration by the tumor.
2.2. Surgery
Preoperative informed consent was acquired in every case,
and the surgeons explained to the patients the details and the
aims of the surgical procedures. Every operation was performed
by the same experienced surgeons within each operative unit,
with a standard surgical technique according to the protocol in
use for the treatment of ATC. The surgical procedure was iden-
tiﬁed as total thyroidectomy, lobectomy or debulking surgery.
Total thyroidectomy (TT) means the total bilateral extracapsular
thyroid removal, while lobectomy (L), consists of resection of one
entire lobe and of the isthmus. Debulking surgery is deﬁned as a
tumor reduction of more than 90%. Cervical lymph node
dissection was performed according to the guidelines of the
American Thyroid Association (ATA) [2]. An ultrasonic scalpel,
Harmonic Ace® (Ethicon Endosurgery), was used during the
dissection in almost 35% of cases [11e13]. In selected cases,
haemostasis was optimised via a Floseal® Hemostatic Matrix
(Baxter, Zurich-Switzerland). Every attempt to preserve the
parathyroid glands and their vascularizations was made. In cases
of suspected devascularised or incidentally removed parathyroid
glands, they were sliced, and direct muscular autoimplantation
in the sternomastoid muscle was subsequently performed.
Serum calcium and iPTH levels were assayed on the ﬁrst post-
operative day and subsequently reassessed evaluating the clin-
ical status.The dissection was carried out after superior and inferior
laryngeal nerves identiﬁcation. In all patients, a drainage was
routinely positioned and removed according to the clinical course.
2.3. Radiotherapy
Multimodal approach of concomitant chemotherapy and
radiotherapy was performed in both adjuvant post surgical and
palliative setting. As postoperative treatment, radiotherapy was
administered at high radiation doses (>40 Gy in radical radio-
therapy), using a hyperfractionated accelerated regimen delivered
by linear accelerators (4e25MV photon or 9e17MeV electron). The
median and most frequently adopted dose was 60 Gy, while about
40 Gy were administered in palliative setting.
2.4. Chemotherapy
Chemotherapy regimen included association of doxorubicin
(50e60 mg/m2/d) and cisplatin (100 mg/m2/d) as standard treat-
ment. Combination of paclitaxel and carboplatin or Tyrosine Kinase
inhibitors, such as sorafenib, were administrated in selective not
responsive cases.
2.5. Statistical methods
Survival curves were generated using the KaplaneMeier
method, and the log-rank test was used for univariate analysis. For
multivariate survival analysis, a Cox proportional hazards model
was used, and p < 0.05 was considered statistically signiﬁcant. All of
the data were analyzed using XLSTAT (Addinsoft, New York, NY,
USA).
3. Results
Patients were divided into two groups for statistical comparison.
In the ﬁrst group (Group A) the tumor main size was less than 5 cm
(61 patients) while in the second (Group B) the neoplasms were
larger than 5 cm (53 patients). In Group A surgery was carried out
in 45 of 61 patients. The related procedures included 40 TT ± lymph
node dissection (88.8%) and 5 palliative L (11.1%). Twenty-six pa-
tients out of 53 (49%) underwent surgery in Group B. TT was per-
formed in 17 patients (65.3%), L in 4 patients (15.3%) while 5
patients were suitable only for a debulking surgery (19.3%).
Radiotherapy was indicated in 74 patients (64.9%), 44 (59.5%) of
Group A and 30 (40.5%) of Group B. Twenty three cases (31.1%),
respectively 12 of Group A (52.1%) and 11 of Group B (47.8%), were
not considered for surgery but only for palliative treatment. In 15 of
74 cases (20.2%), chemotherapy was associated.
Tracheostomy was carried out in 55 cases (48.2%), respectively
in 28 cases (50.9%) of Group A and in 27 cases (49.1%) of Group B. In
22 patients (40%), tracheostomy was performed without further
thyroid surgery.
Endoprothesis was positioned in 27 patients (23.7%), 16 cases
(59.2%) of Group A and 11 cases (40.8%) of Group B; in 19 cases
(70.3%) further cervical surgery was not associated.
Themean survival rate in all 114 patients was 5.35 ± 3.2 months,
respectively 5.9 ± 3.09 months in the Group A and 3.52 ± 3.5
months in the Group B (p ¼ 0.39).
According to Kaplan Meir analysis, considering the role of sur-
gery as treatment of ATC, signiﬁcant difference in survival was
observed comparing Group A vs B (p ¼ 0.013). Multimodal treat-
ment combining surgery and radiotherapy resulted in better
outcome for smaller tumors, less than 5 cm, compared to larger
lesions (p ¼ 0.017). Despite the certain role of combined treatment,
survival was signiﬁcantly improved by surgery alone (Group A:
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(respectively p ¼ 0.047 and p ¼ 0.0001) (Figs. 1 and 2).
4. Discussion
ATC is typically diagnosed in 60 years old people in locally
advanced or metastatic setting. In most of cases, it can be consid-
ered as a not curable disease and treatment is only palliation, based
on a multimodality approach, which is the only chance to improve
survival and quality of life [7].
Surgery is usually the ﬁrst approach used to reduce the tumor
burden and improve at least compressive complications. Unfortu-
nately, up to one-third of patients at the time of clinical presenta-
tion results unsuitable for radical surgery and usually a subtotal
resection with palliative intent is performed. In our series, a sur-
gical procedure was not indicated in 26.3% of patients with a less
than 5 cm tumor and in up to 50% in the group of larger tumors.
Palliative procedures, in association to surgery or as unique treat-
ment, included tracheostomy and endoprothesis insertion. Tra-
cheostomy was carried out in half of the patients, predominantly in
the smaller tumors, without further thyroid surgery. Use of endo-
prothesis was limited to 23.7% of patients and was not associated to
surgery in 70.3% of cases. It was mostly indicated in patients of
Group A.
Consistent clinical experience from the Mayo Clinic, deﬁned
potential predictors of poor survival in histologic type, size of lesion
(6 cm or larger), surgical treatment, local invasiveness and meta-
static disease [9]. We either experienced a signiﬁcant relation be-
tween size of tumor and poor survival considering the limited
indication to radical surgical in case of larger tumors.
Surgical treatment is indicated primarily for relief of airway
obstruction. On the other hand, local control of disease is very
important for clinical management and is associated with longer
survival. Nevertheless, in different series, TT and radical neck
dissection may have no advantages despite of a less aggressive
surgical approach [14,15].
Total thyroidectomy should be recommended in cases of limited
disease, instead debulking surgery can be considered an adequate
option for invasive extended tumors, providing a histopathologicalFig. 1. Survival related to treatment. Tumors <5 cm (group A) and >5 cm (group B).
RTþ (radiotherapy performed), RT (no radiotherapy), SURGþ (surgery performed),
SURG (no surgery). * denotes p < 0.05.diagnosis and a partial symptoms improvement [7]. The impact on
recurrence and survival of cervical lymph node dissection in ATC is
still debated as for DTC [16e19].
In our series, surgery as primary treatment was carried out in
50.8% of patients, most of whom presented a tumor smaller than
5 cm. TT was performed in 90.6% of patients in Group A, whereas in
Group B it was suitable in only 58.4% of cases. In our experience, TT
alone allowed signiﬁcant improvement in survival compared to
best supportive care, especially for tumors larger than 5 cm.
Surgery, followed by chemo-radiotherapy, can signiﬁcantly
improve survival in early stage ATC patients, although this pre-
sentation is extremely rare. In advanced disease is possible to
observe a very poor prognosis, with an overall survival of about 3e6
months. In absence of distant metastases, patients with locally
advanced disease, not suitable for primary surgical resection can be
referred to neoadjuvant chemo-radiotherapy. In these cases,
several advantages in controlling symptoms may be obtained. The
more active and efﬁcient chemotherapy schedule adopted is based
on the combination of doxorubicin and cisplatin. Recently, pacli-
taxel plus carboplatin were used with acceptable results. Biological
agents such sorafenib, axitinib, imatinib and combretastatin A4
were tested in several clinical trials, with encouraging results
[20,21]. ATC was considered a radioresistant tumor. In the past,
radiotherapy was used exclusively in postoperative setting to sta-
bilize surgical excisionwhereas nowadays it can be adopted as part
of neoadjuvant treatment with higher hyperfractionated doses
[22].
As adjuvant approach, either radiotherapy, chemotherapy or
combination could be indicated to improve locoregional control
andmetastatic progression [23]. Radiotherapy is adopted to control
local invasion, in delaying local recurrence and in preventing
thoracic obstruction. Hyperfractionated local radiotherapy has
been shown to be more effective than conventional treatment,
although its toxicity is higher [22]. Usually, survival is higher in
patients with adequate local control whereas poor prognosis affects
those presenting residual local disease or distant metastases. In our
series, radiotherapy was adopted in association to surgery in two
thirds of patients mainly in smaller tumor group (almost 70%). In
our experience, radiotherapy alone offered a signiﬁcant improve-
ment in survival rate compared to best supportive care, especially
in larger tumors.
Radiotherapy in combination with doxorubicin (10 mg/m2)
might offer better results. Patients not suitable for surgery at the
time of diagnosis usually may be referred to a combination of
chemo/radiotherapy, although toxicity seriously affects this treat-
ment [24e27].
Since disappointing results from single therapies, multimodal
approach has progressively become the treatment of choice in ATC,
with surgery being the cornerstone of the management. Nearly all
long-term survivors with ATC have had surgery as part of their
treatment [15]. Our experience conﬁrms that multidisciplinary
treatment combining surgery and radiotherapy offers a signiﬁcant
better outcome in tumors smaller than 5 cm compared to larger
ones.
Tennvall et al. [28] reported similar results analyzing the
outcome of 55 consecutive patients with ATC treated by surgery,
hyperfractionated radiotherapy and chemotherapy. The overall
survival was poor with only 9% of patients surviving 2 years after
treatment. De Crevoisier et al. [29] reported better outcome with
combined therapy, resulting respectively in 1-year survival and a 3-
year survival of 46% and 27% of patients.
Furthermore, Haigh et al. [30] described a restricted group of
long-term survivors treatedwith surgery followed by radiotherapy/
chemotherapy. More speciﬁcally, those patients who underwent a
potentially curative resection had a median survival of 43 months
Fig. 2. Results of survival distribution with Kaplan Meier analysis comparing group A and B. RTþ (radiotherapy performed), RT (no radiotherapy), SURGþ (surgery performed),
SURG (no surgery).
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SwaakeKragten et al. [22] observed that patients with R0/R1
resection followed by chemoradiation achieved a local complete
response rate of 89%, compared to 3% reported in not radiated
patients without R0/R1 resection. Complete local response resulted
in longer median survival (7 months versus 3 months) and
improved 1-year overall survival (32% versus 9%). Levendag et al.
[31] also supported the predictive value of a curative resection. The
above experiences conﬁrm our results about the central role of
surgery in the combined therapeutic protocol for ATC, with a better
long-term survival in selected patients.
Analyzing the available data, debulking surgery followed by
adjuvant chemo-radiotherapy might be the only treatment with an
impact on survival of ATC patients, independently of negative
prognostic factors. Surgery in referral centres might guarantee an
acceptable rate of perioperative morbidity, allowing combined
treatment for ATC patients [32]. Further multicentric studies are
needed to conﬁrm the usefulness of this approach [33].
Nevertheless, the prognosis of ATC remains poor and new
therapeutic strategies might be useful to face this aggressive tumor.
Developing new drugs targeting BRAF, angiogenesis, c-MET and
EGFR, might represent in the future a possible option for unre-
sectable patients [34e37].5. Conclusion
ATC is a killer tumor with a very poor prognosis due to its local
aggressiveness and rapid metastasization. Nowadays surgery still
represent the cornerstone of the management. A multimodalapproach based on surgery, chemotherapy and radiotherapy might
be the only chance to improve survival of locally advanced ATC
patients, especially in tumors smaller than 5 cm. Nevertheless,
further prospective investigations in a multicenter clinical trial
setting are needed to standardize the therapeutic protocol.Ethical approval
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